Rheumatoid factor (RF) is a blood test that measures the amount of the RF antibody in the blood.
How the Test is Performed
Most of the time, blood is drawn from a vein located on the inside of the elbow or the back of the hand.
In infants or young children, a sharp tool called a lancet may be used to puncture the skin.
- The blood collects in a small glass tube called a pipette, or onto a slide or test strip.
- A bandage is put over the spot to stop any bleeding.
How to Prepare for the Test
Most of the time, you do not need to take special steps before this test.
How the Test will Feel
You may feel slight pain or a sting when the needle is inserted. You may also feel some throbbing at the site after the blood is drawn.
Results are usually reported in one of two ways:
- Value, normal less than 15 IU/mL
- Titer, normal less than 1:80 (1 to 80)
If the result is above the normal level, it is positive. A low number (negative result) most often means you do not have rheumatoid arthritis or Sjögren syndrome. However, some people who do have these conditions still have a negative or low RF.
Normal value ranges may vary slightly among different laboratories. Talk to your health care provider about the meaning of your specific test results.
What Abnormal Results Mean
An abnormal result means the test is positive, which means a higher level of RF has been detected in your blood.
- Most people with rheumatoid arthritis or Sjögren syndrome have positive RF tests.
- The higher the level, the more likely one of these conditions is present. There are also other tests for these disorders that help make the diagnosis.
- Not everyone with a higher level of RF has rheumatoid arthritis or Sjögren syndrome.
Your provider should also do another blood test (anti-CCP antibody), to help diagnose rheumatoid arthritis (RA). Anti-CCP antibody is more specific for RA than RF. A positive test for CCP antibody means RA is probably the correct diagnosis.
People with the following diseases may also have higher levels of RF:
- Hepatitis C
- Systemic lupus erythematosus
- Dermatomyositis and polymyositis
- Mixed cryoglobulinemia
- Mixed connective tissue disease
Higher-than-normal levels of RF may be seen in people with other medical problems. However, these higher RF levels cannot be used to diagnose these other conditions:
- AIDS, hepatitis, influenza, infectious mononucleosis, and other viral infections
- Certain kidney diseases
- Endocarditis, tuberculosis, and other bacterial infections
- Parasite infections
- Leukemia, multiple myeloma, and other cancers
- Chronic lung disease
- Chronic liver disease
In some cases, people who are healthy and have no other medical problem will have a higher-than-normal RF level.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588. PMID: 20699241 www.ncbi.nlm.nih.gov/pubmed/20699241.
Andrade F, Darrah E, Rosen A. Autoantibodies in rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017:chap 56.
Hoffmann MH, Trouw LA, Steiner G. Autoantibodies in rheumatoid arthritis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2019:chap 99.
Mason JC. Rheumatic diseases and the cardiovascular system. In: Zipes DP, Libby P, Bonow RO, Mann, DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 94.
Pisetsky DS. Laboratory testing in the rheumatic diseases. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 257.
von Mühlen CA, Fritzler MJ, Chan EKL. Clinical and laboratory evaluation of system rheumatic diseases. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St Louis, MO: Elsevier; 2017:chap 52.
Review Date 4/8/2019
Updated by: Gordon A. Starkebaum, MD, MACR, ABIM Board Certified in Rheumatology, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.